cisapride has been researched along with Cardiomegaly in 1 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cisapride has been shown to have electrophysiological effects on the heart." | 5.40 | Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3. ( Bai, X; Chege Gitau, S; Chu, W; Ju, J; Li, S; Liu, D; Lu, Y; Wu, Y; Xu, C; Yuan, W; Zhang, Q; Zhao, T; Zhou, X, 2014) |
| "Cisapride has been shown to have electrophysiological effects on the heart." | 1.40 | Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3. ( Bai, X; Chege Gitau, S; Chu, W; Ju, J; Li, S; Liu, D; Lu, Y; Wu, Y; Xu, C; Yuan, W; Zhang, Q; Zhao, T; Zhou, X, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, X | 1 |
| Zhang, Q | 1 |
| Zhao, T | 1 |
| Bai, X | 1 |
| Yuan, W | 1 |
| Wu, Y | 1 |
| Liu, D | 1 |
| Li, S | 1 |
| Ju, J | 1 |
| Chege Gitau, S | 1 |
| Chu, W | 1 |
| Xu, C | 1 |
| Lu, Y | 1 |
1 other study available for cisapride and Cardiomegaly
| Article | Year |
|---|---|
Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3.
Topics: Animals; Calcineurin; Cardiomegaly; Cardiotonic Agents; Cisapride; Male; Myocytes, Cardiac; NFATC Tr | 2014 |